tbuckley/cabot-search huggingface dataset:
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Authors: Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, Manish Patel, Myung Ju Ahn, Jeeyun Lee, Todd M. Bauer, Anna F. Farago, Jennifer J. Wheler, Stephen V. Liu, Robert Doebele, Laura Giannetta, Giulio Cerea, Giovanna Marrapese, Michele Schirru, Alessio Amatu, Katia Bencardino, Laura Palmeri, Andrea Sartore-Bianchi, Angelo Vanzulli, Sara Cresta, Silvia Damian, Matteo Duca, Elena Ardini, Gang Li, Jason Christiansen, Karey Kowalski, Ann D. Johnson, Rupal Patel, David Luo, Edna Chow-Maneval, Zachary Hornby, Pratik S. Multani, Alice T. Shaw, Filippo G. De Braud
Journal: Cancer Discovery (2017)

Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions, naïve to prior TKI treatment targeting the specific gene, and who were treated at doses that achieved therapeutic exposures consistent with the recommended phase II dose. Entrectinib was well tolerated, with predominantly Grades 1/2 adverse events that were reversible with dose modification. Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer.Significance: Gene fusions of NTRK1/2/3, ROS1, and ALK (encoding TRKA/B/C, ROS1, and ALK, respectively) lead to constitutive activation of oncogenic pathways. Entrectinib was shown to be well tolerated and active against those gene fusions in solid tumors, including in patients with primary or secondary CNS disease. Cancer Discov; 7(4); 400-9. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 339.
The Allergic Rhinitis Clinical Investigator Collaborative (AR-CIC) - A Correlation Analysis of Specific IgE Levels and Skin Prick Testing with Symptoms Induced via the Nasal Allergen Challenge Model of Allergic Rhinitis
Authors: Jenny Thiele, Lisa M. Steacy, Mena Soliman, Daniel E. Adams, Anne K. Ellis
Journal: Journal of Allergy and Clinical Immunology (2017)
Title in Chemotherapy for Acute Myeloid Leukemia with High Leukocyte Counts.
Authors: Taiichi Kyo, Ryota Imanaka, Tetsuro Ochi, Takeshi Okatani, Kohei Kyo, Mitsuhiro Itagaki, Hisao Nagoshi, Yuta Katayama, Koji Iwato, Hideki Asaoku
Journal: Blood (2014)
High Pri-Mir-181a-1 and Pri-Mir-181a-2 Expression Associates with Improved Outcomes in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning
Authors: Sebastian Schwind, Madlen Jentzsch, Marius Bill, Karoline Schubert, Laura Schmalbrock, Heike Weidner, Laura Kloss, Taqiuddine Gaber, Lynn Bonifacio, Kathrin Wildenberger, Wolfram Pönisch, Vladan Vucinic, Georg-Nikolaus Franke, Thoralf Lange, Michael Cross, Gerhard Behre, Dietger Niederwieser
Journal: Blood (2014)
Study Design, Baseline and Open-Label Results from XTEND-CIU: A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab through 48 Weeks in Patients with Chronic Idiopathic Urticaria
Authors: Thomas B. Casale, Mark D. Scarupa, Michael Holden, Benjamin L. Trzaskoma, Evgeniya Antonova, Patrick H. Win
Journal: Journal of Allergy and Clinical Immunology (2017)
Circulating microRNAs as potential biomarkers in patients with renal tumors.
Authors: Luis M. Antón Aparicio, Vanessa Medina, Manuel Valladares Ayerbes, Isabel Santamarina, Guadalupe Aparicio Gallego, Silvia Diaz Prado, Maria Quindós Varela, Guillermo Alonso-Jaudenes Curbera
Journal: Journal of Clinical Oncology (2012)

405 Background: MicroRNAs (miRNAs), a class of small RNAs, have been intensely investigated recently because of their important regulatory role in gene expression. Circulating miARNs are potential biomarkers for cancer not only abundant in blood, but also very stable, which are important prerequisites as clinical biomarkers. Detection of circulating tumor cells (CTC) may provide diagnostic and prognostic information in genitourinary renal tumors. The aim of this work is identify miRNAs potentially useful for CTC detection in blood samples from patients with renal tumors to assess their potential clinical significance. Methods: We examined blood levels of three miRNAs, let-7c, miR-200c and miR-31 in 48 patients with renal tumors with locally advanced or metastatic disease and 18 healthy persons using quantitative real-time PCR. The clinicopathologic characteristics of the population under consideration include among other: sex, age, tumor location, histological type, Fuhrman grade, tumor size, number of involved nodes, tumor stage, time to progression and overall survival. Results: We found that the median levels of miRNAs, let-7c, miR-200c and miR-31 were significantly higher in patients with renal tumors than those in healthy controls (p=.002, p=.000 and p=.004, respectively). Receiver-operator characteristic (ROC) curve analyses indicate that these blood miRNAs may be useful markers for discriminating patients with renal tumors from healthy controls (AUC=.750, AUC=.853 and AUC=.738, respectively). Conclusions: miRNAs in the circulation are relatively stable, very accessible, low invasive and easily testable biomarkers. Our results suggest let-7c, miR-200c and miR-31 as novel stable blood-based markers for renal cancer detection. This work was supported by Grants PI07/0477 from Fondo de Investigaciones Sanitarias (FIS), Instituto de Salud Carlos III.S. Díaz Prado is supported by an Isidro Parga Pondal research contract by Xunta de Galicia (A Coruña, Galicia, Spain). Cancer research in our laboratory is supported by the “Fundación do CHU A Coruña”.
Prevalence of cognitive impairment in patients with hematologic cancers preceding stem cell transplantation: Program for healthy aging.
Authors: Beatrice Jara-Almonte Edwards, Holly Michelle Holmes, Heather Valladarez, Ming Sun, Peter Khalil, Vu Nguyen, Juhee Song, Richard E. Champlin
Journal: Journal of Clinical Oncology (2016)

32 Background: Older adults, 65 years of age and older, with hematologic cancers may be at higher risk for cognitive impairment. It is postulated that the etiology of cognitive impairment in cancer may a combination of age-related and chemotherapy related cognitive impairment. Methods: We conducted a retrospective cohort analysis, of older adult patients 65 years and older evaluated at the Program for Healthy Aging at MD Anderson from January 1, 2013 through March 31, 2015. Cognitive assessment was evaluated through personal interview, and the Montreal cognitive assessment, functional assessment utilizing ADLs and IADLs. Screening for depression was conducted with the PHQ-9. Patients were interviewed regarding risk factors for dementia including depression, concussions, alcohol abuse, and family history of dementia. Level of education was assessed. Patients were euthymic. Cognitive impairment was defined as an abnormal MOCA without functional impairment, dementia was defined as an abnormal MOCA with functional impairment. Imaging and assessment for reversible factors of memory loss was conducted. SAS 9.4 (SAS Institute INC, Cary, NC) was used for data analysis. Results: The majority of these 62 patients had received chemotherapy for more than 2 years. Cognitive impairment and/or dementia were identified in 50 (80.6%) patients. Types of dementia included Alzheimer’s disease (n = 4, 8%), vascular dementia (n = 5, 10 %), and mixed dementia (n = 15, 30%).Mild cognitive impairment was evidenced in 14 cases (28%) The majority of cases of dementia with known stage were early stage dementia (n = 13, 72.2%), moderate stage dementia (n = 3, 16.7%), and advanced or severe dementia (n = 2, 11.1%). Brain imaging was performed identifying white matter microischemic changes, cerebrovascular accidents and brain atrophy in some cases. No significant thyroid abnormalities, B12 deficiency or other reversible causes were identified. Conclusions: Cognitive impairment and dementia are prevalent in older patients with hematologic malignancies. Identification and management of this condition may prevent delirium and hospital complications during stem cell transplantation.
Higher Proportions of IFNg-Producing T Cells, CD56bright NK Cells and Immature B Cells in the Lymphocytes of G-CSF Stimulated Donor Grafts Are Associated with Less Chronic Gvhd After HSCT: Results From the Canadian BMT Group 0601 Randomized, Phase III Trial
Authors: Sabine Ivison, Aminia Kariminia, Megan Levings, Raewyn Broady, Tony Panzarella, Alisha Albert-Green, Mahmoud Aljurf, Hind Al Humaidan, Ronan Foley, Gerald Devins, Holly Margaret Kerr, Stephanie J Lee, David Swajcer, Cynthia L. Toze, Stephen Couban, Kirk R. Schultz
Journal: Blood (2012)
An APRIL Based Chimeric Antigen Receptor to Simultaneously Target BCMA and TACI in Multiple Myeloma (MM) Has Potent Activity in Vitro and in Vivo
Authors: Lydia Sarah Hui Lee, Benjamin Owen Draper, Neil Chaplin, Brian Philip, Melody Chin, Daria Galas-Filipowicz, Simon Thomas, Evangelia Kokalaki, James Francis, Kwee L Yong, Martin A Pule
Journal: Blood (2016)
Functional characterization of variants of unknown significance (VUS) in patients and their responsiveness to targeted therapy drugs (TTD)
Authors: G. Tarcic, C.M. Walko, H.L. McLeod, J.K. Hicks, Z. Barbash, O. Edelheit, B. Miron, M. Vidne, E. Padron
Journal: Annals of Oncology (2016)
Outcomes After Vena Cava Filter Use in Noncancer Patients With Acute Venous Thromboembolism
Authors: Richard H. White, Ann Brunson, Patrick S. Romano, Zhongmin Li, Ted Wun
Journal: Circulation (2016)

Evidence that vena cava filters (VCFs) are beneficial is limited.We retrospectively analyzed all noncancer patients admitted to nonfederal California hospitals for acute venous thromboembolism from 2005 to 2010. Analysis was stratified by the presence/absence of a contraindication to anticoagulation (active bleeding, major surgery). Outcomes were death within 30 or 90 days of admission and the 1-year incidence of recurrent venous thromboembolism manifested as pulmonary embolism or deep vein thrombosis. Propensity score methods were used to account for observed systematic differences in baseline characteristics between patients treated and those not treated with a VCF. Among 80 697 patients with no contraindication to anticoagulation, VCF use (n=7762, 9.6%) did not significantly reduce the 30-day risk of death (hazard ratio [HR], 1.12; 95% confidence interval [CI], 0.98-1.28). Among 3017 patients with active bleeding, VCF use (n=1095, 36.3%) reduced the 30-day risk of death by 32% (HR, 0.68; 95% CI, 0.52-0.88) and the 90-day risk by 27% (HR, 0.73; 95% CI, 0.59-0.90). VCF use (n=489, 33.8%) did not reduce mortality among 1445 patients who underwent major surgery (HR, 1.1; 95% CI, 0.71-1.77). In all subgroups, filter use did not reduce the risk of subsequent pulmonary embolism. However, the risk of subsequent deep vein thrombosis increased by 50% among VCF patients with no contraindication (HR, 1.53; 95% CI, 1.34-1.74) and by 135% among VCF patients with active bleeding (HR, 2.35; 95% CI, 1.56-3.52).VCF use significantly reduced the short-term risk of death only among patients with acute venous thromboembolism who had a contraindication to anticoagulation because of active bleeding. These results support the findings of a randomized clinical trial and current guidelines that recommend VCF use only in patients who cannot receive anticoagulation treatment.
Doublet Versus Triplet PET: Is END of Therapy PET Needed IF Interim PET Is Negative in Hodgkin'S or Diffuse Large B CELL Lymphoma?
Authors: Imran K Tailor, Bilal Btoosh, Shaimaa Hamdy, Shanker Raja, Mohammed O Alharbi, Ibraheem H Motabi, Nawal Faiez Alshehry, Mohammed S Qureshi, Mubarak S. AlGhamdi, Syed Ziauddin A. Zaidi
Journal: Blood (2016)
Metabolic evaluation of sporadic papillary kidney cancer.
Authors: Brian Shuch, Christopher Ricketts, Carole Sourbier, Shinji Tsutsumi, Xiu-ying Zhang, Arie S. Belldegrun, Christopher G. Wood, W. Marston Linehan, Len Neckers
Journal: Journal of Clinical Oncology (2012)

377 Background: Papillary kidney cancer, which occurs in 15% of patients with kidney cancer, can be aggressive and there is currently no effective form of therapy for this disease. To evaluate the metabolic characteristics of sporadic papillary kidney cancer, we have evaluated metabolic parameters of several papillary kidney cancer cell lines and available gene expression profiles. Methods: Established cell lines derived from patients with sporadic papillary kidney cancer (LABAZ, MDACC-55, HRC-86T2) and from a hereditary form of fumarate hydratase-deficient kidney cancer (UOK262) were evaluated. All sporadic lines were initially sequenced for fumarate hydratase (FH). All cell lines were metabolically profiled using the Seahorse Extracellular Flux Analyzer and further evaluated for reactive oxygen species (ROS), mitochondrial membrane potential, and glucose dependence. Finally gene expression profiles of publically available datasets of papillary and HLRCC tumors were downloaded, normalized, and analyzed. Results: Sporadic lines had no alterations in FH and metabolic analysis demonstrated normal oxygen consumption and minimal lactate production, in contrast to highly glycolytic UOK262. Also unlike UOK262, the sporadic papillary kidney cancer lines were not sensitive to glucose withdrawal, had low levels of ROS, and had normal mitochondria membrane potential. Principal component analysis (PCA) demonstrated that HLRCC tumor specimens are very different from sporadic papillary tumors at the molecular level. Conclusions: Our study of established sporadic papillary RCC and fumarate hydratase-deficient HLRCC cell line together with analysis of available gene expression profiles demonstrates that these sporadic papillary kidney cancer cell lines appear to have a distinct metabolic profile from those in the fumarate hydratase deficient kidney cancer cell line. Understanding the metabolic basis of papillary kidney cancer could provide the foundation for the development of targeted approaches to therapy for patients with this disease.
Major Superiority of Melphalan - Prednisone (MP) + Thalidomide (THAL) over MP and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients with Multiple Myeloma.
Authors: Thierry Facon, J.Y. Mary, C. Hulin, L. Benboubker, M. Attal, M. Renaud, J.L. Harousseau, B. Pegourie, G. Guillerm, C. Chaleteix, M. Dib, L. Voillat, H. Maisonneuve, J. Troncy, V. Dorvaux, M. Monconduit, C. Martin, P. Casassus, J. Jaubert, H. Jardel, B. Kolb, F. Bauters
Journal: Blood (2005)
An Open Label, Dose Escalation Study of AVE9633 Administered as a Single Agent by Intravenous (IV) Infusion Weekly for 2 Weeks in 4-Week Cycle to Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML).
Authors: Ollivier Legrand, Maria B. Vidriales, Xavier Thomas, Charles Dumontet, Anne Vekhoff, Rodica Morariu-Zamfir, John Lambert, Jesus F. San Miguel, Jean-Pierre Marie
Journal: Blood (2007)
Overcoming docetaxel resistance in advanced castration-resistant prostate cancer (CRPC): A phase I/II trial of the combination of temsirolimus and docetaxel.
Authors: Ignacio Duran, Clara Montagut, Emiliano Calvo, Susana Galtes, Alicia Navarrete, Jesus Rodriguez-Pascual, Manuel Hidalgo, Juan Francisco Rodriguez-Moreno, Antonio Cubillo, Antonia Garcia, Lorena Sanchez, Coral Barbas, Andrea Viqueira, Joaquim Bellmunt
Journal: Journal of Clinical Oncology (2012)

250 Background: Mechanisms of resistance to docetaxel (D) are not fully understood. Preclinical work showed that administration of temsirolimus (T) between courses of D delays the growth of PTEN deficient tumors in xenografts. (Wu et al. Cancer Res 2005) The current study aims to determine the recommended phase II dose (RPTD), toxicity, pharmacokinetics (PK) and preliminary activity of D in combination with T in CRPC patients (pts). Methods: Pts aged ≥ 18 with advanced solid tumors refractory to standard therapy, ECOG ≤2, adequate bone marrow and renal function were eligible. D was given once q. 3 weeks along with T on days 2, 9 &amp;16. The protocol was later amended and day 9 of T omitted due to excessive myelotoxicity. A 3+3 rule dose escalation was used with the next dose levels (DL) planned: DL1: D 50mg/m2, T 15 mg; DL2: D 65mg/m2, T 15 mg; DL3: D 75mg/m2, T 15 mg; DL4: D 75mg/m2, T 25 mg. An expanded cohort for pts with CRPC who have progressed to D will enroll pts once the RPTD has been defined. Results: To date 13 pts have been enrolled, median age = 65 (range 35–76), 9 male and 8 ECOG 0, Forty-seven cycles (median: 2; range: 1–9) were administered. The most frequent related adverse events (AEs) of all grades expressed as % of cycles were: leucopenia (80.8%), hyperglycemia (70.2%), anemia (68.1%) and hypercholesterolemia (65.9%). The most common Grade 3–4 AEs as % of cycles were: leucopenia (27.6%), neutropenia (29.7%), and hypophosphatemia (23%). Two pts in DL2 experienced dose limiting toxicities (DLT) consisting of intolerable grade 2 mucositis and febrile neutropenia respectively. DL1 was expanded and 3 additional pts treated with no DLTs. No drug-drug PK interactions were observed. Among 13 pts evaluable for response, 6 (2 pancreas, 2 CRPC, 1 rectal and 1 sarcoma) achieved stable disease. One pt with CRPC who had previously progressed on docetaxel received 9 cycles of treatment with sustained clinical benefit. The expanded cohort for CRPC patients is opened and recruiting. Conclusions: T and D can be safely combined at reduced doses of both agents with no PK interaction. Preliminary antitumor activity has been observed in CRPC patients. Data on the expanded cohort will be presented.
Loss of the Cell Cycle Regulator p26INCA1 Induces Exhaustion of Leukemic Stem Cells
Authors: Petra Tschanter, Nicole Baeumer, Lisa Lohmeyer, Frank Berkenfeld, Lara Tickenbrock, Sven Diederichs, Martin Stehling, Gabriele Köhler, Hubert Serve, Wolfgang E. Berdel, Steffen Koschmieder, Carsten Müller-Tidow
Journal: Blood (2010)
Early Response Characteristics and Blast Cytogenetic FEatures In 5,377 Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): A Children's Oncology Group (COG) Study
Authors: Kelly W. Maloney, Mignon L. Loh, Elizabeth Raetz, Michael J. Borowitz, Meenakshi Devidas, Alison M. Friedmann, Leonard A. Mattano, Brent Wood, Naomi Winick, Stephen Hunger, William L. Carroll
Journal: Blood (2010)
Tumor necrosis factor alpha G(-244)A(-238) haplotype is associated with lower risk of restenosis after percutaneous coronary intervention
Authors: PS Monraats, NM Pires, A Schepers, AH Zwinderman, MP de Maat, RJ de Winter, RA Tio, PA Doevendans, J Waltenberger, A van der Laarse, E vander Wal, J Wouter
Journal: Circulation (2004)
Effects of Soluble Domain 1 of Apolipoprotein ER2′ (BD1 apoER2′) on Pathogenic Effects of a Dimer of β2glycoprotein I (β2GPI) In Vivo.
Authors: Silvia S. Pierangeli, Zurina Romay-Penabad, R.T. Urbanus, Guadalupe Montiel-Manzano, M.T. Pennings, Ronald Derksen, Philip deGroot
Journal: Blood (2007)
MRSA菌血症後に滲出性収縮性心膜炎(effusive-CP)を発症した症例
Authors: 岡本尚子, 野間貴久, 石原靖大, 北泉顕二, 瀧波裕之, 吉田潤史, 四宮かおり, 岩藤泰慶, 雪入一志, 大森浩二, 河野雅和
Journal: Circulation (2009)
Favorable Immune Reconstitution After Nonmyeloablative, T-Cell Replete, HLA-Haploidentical BMT with Post-Transplant Cyclophosphamide
Authors: Heather J. Symons, Chimene Kesserwan, Ferdynand Kos, Christopher J. Thoburn, Ashley T. Munchel, Wendy Ying, Leo Luznik, Hyam I. Levitsky, Richard J. Jones, Allan D. Hess, Ephraim J. Fuchs
Journal: Blood (2011)
Quality of Leukemia-Derived Dendritic Cells (DC) and T-Cells Are Predictive for the Specific Anti-Leukemic Potential of DC-Trained T-Cells.
Authors: Helga Schmetzer, Christine Grabrucker, Anja Liepert, Andreas Kremser, Julia Loibl, Markus Freudenreich, Reibke Roland, Raymund Buhmann, Ting Yang, Christoph Schmid, Tanja Kroell, Hans-Jochem Kolb
Journal: Blood (2007)
A Comparison of 1 Antigen-Mismatched Related and Matched Unrelated Transplants.
Authors: Poliana Patah, Rima Saliba, Marcelo Fernandez-Vina, Pedro Cano, Susana Pesoa, Gabriela Rondon, Borje Andersson, Sergio Giralt, Partow Kebriaei, Chitra Hosing, Paolo Anderlini, Daniel Couriel, Amin Alousi, Leandro Padua, Carlos Ramos, Richard Champlin, Marcos de Lima
Journal: Blood (2007)
A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma
Authors: P.A. Ott, A.C. Pavlick, D.B. Johnson, L.L. Hart, J.R. Infante, J.J. Luke, J. Lutzky, N. Rothschild, L. Spitler, C.L. Cowey, A. Alizadeh, A. Salama, Y. He, R.G. Bagley, J. Zhang, O. Hamid
Journal: Annals of Oncology (2016)
Use of meta-analysis of clear cell renal cell carcinoma gene expression to define a variant subgroup and identify gender influences on tumor biology.
Authors: Scott Mattox Haake, A. Rose Brannon, Kate Hacker, Raj Pruthi, Eric Wallen, Matthew Edward Nielsen, Kimryn Rathmell
Journal: Journal of Clinical Oncology (2012)

412 Background: Clear cell renal cell carcinoma (ccRCC) displays molecular and histological heterogeneity. Previously described subsets of this disease, ccA and ccB, were defined based on multi-gene expression profiles, but it is unclear if these subgroupings reflect the full spectrum of disease or how these molecular subtypes relate to histological descriptions or gender. We sought to determine whether additional subtypes of ccRCC exist, and whether these subtypes are related to VHL inactivation, HIF1/HIF2 expression, tumor histology, or gender. Methods: Six large publically available ccRCC gene expression databases were identified that cumulatively provided data for 480 tumors for meta-analysis via meta-array compilation. Unsupervised consensus clustering was performed on the meta-arrays. Tumors were examined for the relationship of multigene-defined consensus subtypes and expression signatures of VHL mutation and HIF status, tumor histology, and gender. Results: Two dominant subsets of ccRCC were observed. However, a minor third cluster was revealed which correlated strongly with a wild type VHL expression profile and indications of variant histologies. When variant histologies were removed, ccA tumors naturally divided by gender. This technique is limited by potential for persistent batch effect, tumor sampling bias, and restrictions of annotated information. Conclusions: ccA and ccB subsets of ccRCC are robust in meta-analysis among histologically conventional ccRCC tumors. A third group of tumors was identified, which may represent a new variant of ccRCC. Within definitively clear cell tumors, gender may delineate tumors in such a way that could have implications regarding current treatments and future drug development.
Depletion of Regulatory T Cells Dramatically Improves DC-Based Immunization Against Acute Myeloid Leukemia.
Authors: Stephanie Delluc, Auguste Gaston, Carmen Marchiol-Fournigault, Didier Fradelizi, Armelle Regnault, Kim Hanh Le Quan Sang, Lea Tourneur, Gilles Chiocchia, Agnes Buzyn
Journal: Blood (2006)
Impact of Megakaryocyte Morphology on Prognosis of Persons with Myelodysplastic Syndromes
Authors: Gege Feng, Wen Cui, Wenyu Cai, Tiejun Qin, Yue Zhang, Zefeng Xu, Liwei Fang, Hongli Zhang, Lijuan Pan, Naibo Hu, Bing Li, Zhijian Xiao
Journal: Blood (2015)
Mast cell Tryptase and Carboxypeptidase A3 (CPA3) as Markers for Predicting Susceptibility to Severe Allergic Drug Reactions
Authors: Rana Abadalkareem, Laurie C.K. Lau, Ahmed Abdelmotelb, Xiaoying Zhou, Efrem Eren, Andrew F. Walls
Journal: Journal of Allergy and Clinical Immunology (2017)